BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dezecapavir readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dezecapavir\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07934719-977@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270218
DTEND;VALUE=DATE:20270219
SUMMARY:Dezecapavir: Phase 1 readout est. (NCT07934719)
DESCRIPTION:Dezecapavir\, phase 1\, HIV.\nStudy: Mass Balance and Absolute 
 Bioavailability of [14C]-VH4011499\nEstimated primary completion: 18 Febru
 ary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dezecapavir
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079
 34719
URL:https://assetmemo.bio/drug/dezecapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939594-977@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Dezecapavir: Phase 1 readout est. (NCT07939594)
DESCRIPTION:Dezecapavir\, phase 1\, HIV.\nStudy: An Evaluation of the Poten
 tial for VH4011499 Drug-drug-interactions\nEstimated primary completion: 1
 2 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dezecap
 avir#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07939594
URL:https://assetmemo.bio/drug/dezecapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06724640-977@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20280816
DTEND;VALUE=DATE:20280817
SUMMARY:Dezecapavir: Phase 1 readout est. (NCT06724640)
DESCRIPTION:Dezecapavir\, phase 1\, HIV.\nStudy: A Study to Assess the Safe
 ty\, Tolerability\, and Pharmacokinetics of VH4011499 Compared to Placebo 
 in Adults Without HIV\nEstimated primary completion: 16 August 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/dezecapavir#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06724640
URL:https://assetmemo.bio/drug/dezecapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07816250-977@assetmemo.bio
DTSTAMP:20261121T004100Z
DTSTART;VALUE=DATE:20320610
DTEND;VALUE=DATE:20320611
SUMMARY:Dezecapavir: Phase 2 readout est. (NCT07816250)
DESCRIPTION:Dezecapavir\, phase 2\, HIV.\nStudy: A Phase 2b Study Evaluatin
 g VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in T
 reatment Naïve Adults (CINERGY)\nEstimated primary completion: 10 June 20
 32. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dezecapavir#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07816250
URL:https://assetmemo.bio/drug/dezecapavir#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
